Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors

ACS Nano

Volumn 9, Issue 3, 2015, Pages 2377-2389

  Van Rijt, Sabine H ^a   Bölükbas, Deniz A ^a   Argyo, Christian ^b   Datz, Stefan ^b   Lindner, Michael ^b   Eickelberg, Oliver ^a   Königshoff, Melanie ^a   Bein, Thomas ^b   Meiners, Silke ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

bortezomib; cisplatin; combination treatment; controlled drug delivery; ex vivo 3D lung tissue cultures; lung cancer; matrix metalloproteinase 9; mesoporous silica nanoparticles; nanomedicine

Indexed keywords

BIOLOGICAL ORGANS; CELL DEATH; DIAGNOSIS; DISEASE CONTROL; DISEASES; MAMMALS; MEDICAL NANOTECHNOLOGY; MESOPOROUS MATERIALS; NANOPARTICLES; RESPIRATORY SYSTEM; SILICA; SILICA NANOPARTICLES; SYNTHESIS (CHEMICAL); TARGETED DRUG DELIVERY; TISSUE CULTURE; TUMORS;

BORTEZOMIB; CIS-PLATIN; COMBINATION TREATMENTS; EX-VIVO; LUNG CANCER; MATRIX METALLOPROTEINASE-9; MESOPOROUS SILICA NANOPARTICLES;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; DRUG CARRIER; GELATINASE B; NANOPARTICLE; SILICON DIOXIDE;

ANIMAL; CHEMISTRY; DRUG RELEASE; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; MUTATION; PARTICLE SIZE; PATHOLOGY; POROSITY; TISSUE CULTURE TECHNIQUE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CELL LINE, TUMOR; CISPLATIN; DRUG CARRIERS; DRUG LIBERATION; FEMALE; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICE; MUTATION; NANOPARTICLES; PARTICLE SIZE; POROSITY; SILICON DIOXIDE; TISSUE CULTURE TECHNIQUES;

EID: 84925688271     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn5070343     Document Type: Article

References (51)

1. Malam, Y.; Lim, E. J.; Seifalian, A. M. Current Trends in the Application of Nanoparticles in Drug Delivery Curr. Med. Chem. 2011, 18, 1067-1078
2. Egeblad, M.; Werb, Z. New Functions for the Matrix Metalloproteinases in Cancer Progression Nat. Rev. Cancer 2002, 2, 161-174
3. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of Matrix Metalloproteinases in Cancer Progression and Their Pharmacological Targeting FEBS J. 2011, 278, 16-27
4. Iniesta, P.; Moran, A.; De Juan, C.; Gomez, A.; Hernando, F.; Garcia-Aranda, C.; Frias, C.; Diaz-Lopez, A.; Rodriguez-Jimenez, F. J.; Balibrea, J. L. et al. Biological and Clinical Significance of Mmp-2, Mmp-9, Timp-1 and Timp-2 in Non-Small Cell Lung Cancer Oncol. Rep. 2007, 17, 217-223
5. Martins, S. J.; Takagaki, T. Y.; Silva, A. G.; Gallo, C. P.; Silva, F. B.; Capelozzi, V. L. Prognostic Relevance of Ttf-1 and Mmp-9 Expression in Advanced Lung Adenocarcinoma Lung Cancer 2009, 64, 105-109
6. Turk, B. E.; Huang, L. L.; Piro, E. T.; Cantley, L. C. Determination of Protease Cleavage Site Motifs Using Mixture-Based Oriented Peptide Libraries Nat. Biotechnol. 2001, 19, 661-667
7. Li, H.; Yu, S. S.; Miteva, M.; Nelson, C. E.; Werfel, T.; Giorgio, T. D.; Duvall, C. L. Matrix Metalloproteinase Responsive, Proximity-Activated Polymeric Nanoparticles for SiRNA Delivery Adv. Funct. Mater. 2013, 23, 3040-3052
8. Chien, M. P.; Carlini, A. S.; Hu, D. H.; Barback, C. V.; Rush, A. M.; Hall, D. J.; Orr, G.; Gianneschi, N. C. Enzyme-Directed Assembly of Nanoparticles in Tumors Monitored by in Vivo Whole Animal Imaging and ex Vivo Super-Resolution Fluorescence Imaging J. Am. Chem. Soc. 2013, 135, 18710-18713
9. Yamada, R.; Kostova, M. B.; Anchoori, R. K.; Xu, S.; Neamati, N.; Khan, S. R. Biological Evaluation of Paclitaxel-Peptide Conjugates as a Model for Mmp2-Targeted Drug Delivery Cancer Biol. Ther. 2010, 9, 192-203
10. Zhu, L.; Kate, P.; Torchilin, V. P. Matrix Metalloprotease 2-Responsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting ACS Nano 2012, 6, 3491-3498
11. Chien, M. P.; Thompson, M. P.; Barback, C. V.; Ku, T. H.; Hall, D. J.; Gianneschi, N. C. Enzyme-Directed Assembly of a Nanoparticle Probe in Tumor Tissue Adv. Mater. 2013, 25, 3599-3604
12. Gu, G.; Xia, H.; Hu, Q.; Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Tu, Y.; Pang, Z.; Song, Q. et al. Peg-Co-Pcl Nanoparticles Modified with Mmp-2/9 Activatable Low Molecular Weight Protamine for Enhanced Targeted Glioblastoma Therapy Biomaterials 2013, 34, 196-208
13. Hatakeyama, H.; Akita, H.; Ito, E.; Hayashi, Y.; Oishi, M.; Nagasaki, Y.; Danev, R.; Nagayama, K.; Kaji, N.; Kikuchi, H. et al. Systemic Delivery of SiRNA to Tumors Using a Lipid Nanoparticle Containing a Tumor-Specific Cleavable PEG-Lipid Biomaterials 2011, 32, 4306-4316
14. Argyo, C.; Weiss, V.; Bräuchle, C.; Bein, T. Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery Chem. Mater. 2014, 26, 435-451
15. Li, Z.; Barnes, J. C.; Bosoy, A.; Stoddart, J. F.; Zink, J. I. Mesoporous Silica Nanoparticles in Biomedical Applications Chem. Soc. Rev. 2012, 41, 2590-2605
16. Cauda, V.; Schlossbauer, A.; Kecht, J.; Zurner, A.; Bein, T. Multiple Core-Shell Functionalized Colloidal Mesoporous Silica Nanoparticles J. Am. Chem. Soc. 2009, 131, 11361-11370
17. Sauer, A. M.; Schlossbauer, A.; Ruthardt, N.; Cauda, V.; Bein, T.; Brauchle, C. Role of Endosomal Escape for Disulfide-Based Drug Delivery from Colloidal Mesoporous Silica Evaluated by Live-Cell Imaging Nano Lett. 2010, 10, 3684-3691
18. Zhao, Y. L.; Li, Z.; Kabehie, S.; Botros, Y. Y.; Stoddart, J. F.; Zink, J. I. pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles J. Am. Chem. Soc. 2010, 132, 13016-13025
19. Giri, S.; Trewyn, B. G.; Stellmaker, M. P.; Lin, V. S. Y. Stimuli-Responsive Controlled-Release Delivery System Based on Mesoporous Silica Nanorods Capped with Magnetic Nanoparticles Angew. Chem., Int. Ed. 2005, 44, 5038-5044
20. Aznar, E.; Mondragon, L.; Ros-Lis, J. V.; Sancenon, F.; Marcos, M. D.; Martinez-Manez, R.; Soto, J.; Perez-Paya, E.; Amoros, P. Finely Tuned Temperature-Controlled Cargo Release Using Paraffin-Capped Mesoporous Silica Nanoparticles Angew. Chem., Int. Ed. 2011, 50, 11172-11175
21. Popat, A.; Liu, J.; Lu, G. Q.; Qiao, S. Z. A pH-Responsive Drug Delivery System Based on Chitosan Coated Mesoporous Silica Nanoparticles J. Mater. Chem. 2012, 22, 11173-11178
22. Schlossbauer, A.; Kecht, J.; Bein, T. Biotin-Avidin as a Protease-Responsive Cap System for Controlled Guest Release from Colloidal Mesoporous Silica Angew. Chem., Int. Ed. 2009, 48, 3092-3095
23. Mackowiak, S. A.; Schmidt, A.; Weiss, V.; Argyo, C.; von Schirnding, C.; Bein, T.; Brauchle, C. Targeted Drug Delivery in Cancer Cells with Red-Light Photoactivated Mesoporous Silica Nanoparticles Nano Lett. 2013, 13, 2576-2583
24. Bae, M.; Cho, S.; Song, J.; Lee, G. Y.; Kim, K.; Yang, J.; Cho, K.; Kim, S. Y.; Byun, Y. Metalloprotease-Specific Poly(Ethylene Glycol) Methyl Ether-Peptide-Doxorubicin Conjugate for Targeting Anticancer Drug Delivery Based on Angiogenesis Drugs Exp. Clin. Res. 2003, 29, 15-23
25. Bauvois, B. New Facets of Matrix Metalloproteinases MMP-2 and MMP-9 as Cell Surface Transducers: Outside-in Signaling and Relationship to Tumor Progression Biochim. Biophys. Acta 2012, 1825, 29-36
26. Cauda, V.; Schlossbauer, A.; Bein, T. Bio-Degradation Study of Colloidal Mesoporous Silica Nanoparticles: Effect of Surface Functionalization with Organo-Silanes and Poly(Ethylene Glycol) Microporous Mesoporous Mater. 2010, 132, 60-71
27. Cauda, V.; Argyo, C.; Bein, T. Impact of Different Pegylation Patterns on the Long-Term Bio-Stability of Colloidal Mesoporous Silica Nanoparticles J. Mater. Chem. 2010, 20, 8693-8699
28. Dubey, S.; Powell, C. A. Update in Lung Cancer 2007 Am. J. Respir. Crit. Care Med. 2008, 177, 941-946
29. Davies, A. M.; Lara, P. N., Jr.; Mack, P. C.; Gandara, D. R. Incorporating Bortezomib into the Treatment of Lung Cancer Clin. Cancer Res. 2007, 13, s4647-4651
30. Besse, B.; Planchard, D.; Veillard, A. S.; Taillade, L.; Khayat, D.; Ducourtieux, M.; Pignon, J. P.; Lumbroso, J.; Lafontaine, C.; Mathiot, C. et al. Phase 2 Study of Frontline Bortezomib in Patients with Advanced Non-Small Cell Lung Cancer Lung Cancer 2012, 76, 78-83
31. Johnson, L.; Mercer, K.; Greenbaum, D.; Bronson, R. T.; Crowley, D.; Tuveson, D. A.; Jacks, T. Somatic Activation of the K-Ras Oncogene Causes Early Onset Lung Cancer in Mice Nature 2001, 410, 1111-1116
32. Mills, N. E.; Fishman, C. L.; Rom, W. N.; Dubin, N.; Jacobson, D. R. Increased Prevalence of K-Ras Oncogene Mutations in Lung Adenocarcinoma Cancer Res. 1995, 55, 1444-1447
33. Cancer Genome Atlas Network. Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature 2014, 511, 543-550.
34. The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM). A Genomics-Based Classification of Human Lung Tumors. Sci. Trans. Med. 2013, 5, 209ra153.
35. Dasari, S.; Bernard Tchounwou, P. Cisplatin in Cancer Therapy: Molecular Mechanisms of Action Eur. J. Pharmacol. 2014, 740C, 364-378
36. Rink, J. S.; Plebanek, M. P.; Tripathy, S.; Thaxton, C. S. Update on Current and Potential Nanoparticle Cancer Therapies Curr. Opin. Oncol. 2013, 25, 646-651
37. Taratula, O.; Garbuzenko, O. B.; Chen, A. M.; Minko, T. Innovative Strategy for Treatment of Lung Cancer: Targeted Nanotechnology-Based Inhalation Co-delivery of Anticancer Drugs and SiRNA J. Drug Targeting 2011, 19, 900-914
38. Kulkarni, P. S.; Haldar, M. K.; Nahire, R. R.; Katti, P.; Ambre, A. H.; Muhonen, W. W.; Shabb, J. B.; Padi, S. K.; Singh, R. K.; Borowicz, P. P. et al. MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer Mol. Pharmaceutics 2014, 11, 2390-2399
39. Liu, Q.; Li, R. T.; Qian, H. Q.; Yang, M.; Zhu, Z. S.; Wu, W.; Qian, X. P.; Yu, L. X.; Jiang, X. Q.; Liu, B. R. Gelatinase-Stimuli Strategy Enhances the Tumor Delivery and Therapeutic Efficacy of Docetaxel-Loaded Poly(Ethylene Glycol)-Poly(Varepsilon-Caprolactone) Nanoparticles Int. J. Nanomed. 2012, 7, 281-295
40. Singh, N.; Karambelkar, A.; Gu, L.; Lin, K.; Miller, J. S.; Chen, C. S.; Sailor, M. J.; Bhatia, S. N. Bioresponsive Mesoporous Silica Nanoparticles for Triggered Drug Release J. Am. Chem. Soc. 2011, 133, 19582-19585
41. Zhang, J.; Yuan, Z. F.; Wang, Y.; Chen, W. H.; Luo, G. F.; Cheng, S. X.; Zhuo, R. X.; Zhang, X. Z. Multifunctional Envelope-Type Mesoporous Silica Nanoparticles for Tumor-Triggered Targeting Drug Delivery J. Am. Chem. Soc. 2013, 135, 5068-5073
42. Xu, J. H.; Gao, F. P.; Li, L. L.; Ma, H. L.; Fan, Y. S.; Liu, W.; Guo, S. S.; Zhao, X. Z.; Wang, H. Gelatin-Mesoporous Silica Nanoparticles as Matrix Metalloproteinases-Degradable Drug Delivery Systems in Vivo Microporous Mesoporous Mater. 2013, 182, 165-172
43. Neuhaus, V.; Schwarz, K.; Klee, A.; Seehase, S.; Forster, C.; Pfennig, O.; Jonigk, D.; Fieguth, H. G.; Koch, W.; Warnecke, G. et al. Functional Testing of an Inhalable Nanoparticle Based Influenza Vaccine Using a Human Precision Cut Lung Slice Technique PLoS One 2013, 8, e71728
44. Paranjpe, M.; Neuhaus, V.; Finke, J. H.; Richter, C.; Gothsch, T.; Kwade, A.; Buttgenbach, S.; Braun, A.; Muller-Goymann, C. C. In Vitro and Ex Vivo Toxicological Testing of Sildenafil-Loaded Solid Lipid Nanoparticles Inhalation Toxicol. 2013, 25, 536-543
45. Nassimi, M.; Schleh, C.; Lauenstein, H. D.; Hussein, R.; Lubbers, K.; Pohlmann, G.; Switalla, S.; Sewald, K.; Muller, M.; Krug, N. et al. Low Cytotoxicity of Solid Lipid Nanoparticles in in Vitro and Ex Vivo Lung Models Inhalation Toxicol. 2009, 21 (Suppl 1) 104-109
46. Uberall, I.; Kolar, Z.; Trojanec, R.; Berkovcova, J.; Hajduch, M. The Status and Role of Erbb Receptors in Human Cancer Exp. Mol. Pathol. 2008, 84, 79-89
47. Eberhard, D. A.; Johnson, B. E.; Amler, L. C.; Goddard, A. D.; Heldens, S. L.; Herbst, R. S.; Ince, W. L.; Janne, P. A.; Januario, T.; Johnson, D. H. et al. Mutations in the Epidermal Growth Factor Receptor and in Kras Are Predictive and Prognostic Indicators in Patients with Non-Small-Cell Lung Cancer Treated with Chemotherapy Alone and in Combination with Erlotinib J. Clin. Oncol. 2005, 23, 5900-5909
48. Cappuzzo, F.; Varella-Garcia, M.; Finocchiaro, G.; Skokan, M.; Gajapathy, S.; Carnaghi, C.; Rimassa, L.; Rossi, E.; Ligorio, C.; Di Tommaso, L. et al. Primary Resistance to Cetuximab Therapy in Egfr Fish-Positive Colorectal Cancer Patients Br. J. Cancer 2008, 99, 83-89
49. Roy, R.; Yang, J.; Moses, M. A. Matrix Metalloproteinases as Novel Biomarkers and Potential Therapeutic Targets in Human Cancer J. Clin. Oncol. 2009, 27, 5287-5297
50. Itoh, T.; Tanioka, M.; Matsuda, H.; Nishimoto, H.; Yoshioka, T.; Suzuki, R.; Uehira, M. Experimental Metastasis Is Suppressed in MMP-9-Deficient Mice Clin. Exp. Metastasis 1999, 17, 177-181
51. Davies, A. M.; Lara, P. N.; Lau, D. H.; Mack, P. C.; Gumerlock, P. H.; Gandara, D. R.; Schenkein, D.; Doroshow, J. H. The Proteasome Inhibitor, Bortezomib, in Combination with Gemcitabine (Gem) and Carboplatin (Carbo) in Advanced Non-Small Cell Lung Cancer (Nsclc): Final Results of a Phase I California Cancer Consortium Study J. Clin. Oncol. 2004, 22, 642s-642s